Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling (BIOCARDIUM-HF)

University of Zurich (UZH)

Status: Not yet enrolling

Conditions: Heart Failure; Heart Failure (for Example, Fluid Overload)

Study type: Observational

Funder types: Other

Identifiers

NCT07158086

25_0908

Details and patient eligibility

About

The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients.

The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.

Enrollment: 500 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

INCLUSION CRITERIA

• Female and Male, age ≥18 years at screening.
• Diagnosis of Heart Failure according to ESC Heart Failure Guidelines
• Ability to understand the requirements of the study and to provide informed consent.
• Willingness to undergo follow-up.

EXCLUSION CRITERIA

Patients will be excluded if they meet any of the following conditions:

• Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy).
• Autoimmune or systemic inflammatory diseases.
• Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B/C with elevated transaminases).

Other exclusion criteria:

• Age<18 years old
• Inability to provide written informed consent

Trial design

500 participants in 3 patient groups

Heart Failure with reduced ejection fraction (HFrEF)

Description:

LVEF \<40%

Heart Failure with preserved ejection fraction (HFpEF)

Description:

LVEF \>50%

Heart Failure with mildyly reduced ejection fraction (HFmrEF)

Description:

LVEF \>40% and \<50%